Much to-do has been made about the FDA's draft guidance on developing drugs for early stage Alzheimer's disease (AD), but some people are missing the point, especially if they think the agency is "loosening" its standards for Alzheimer's treatments, according to an FDA official. Read More
By using a single-cell proteomics approach, researchers have discovered that the mammalian target of rapamycin, or mTOR protein, may be hardest to drug at oxygen levels that are often found in tumors. Read More
Themis Bioscience GmbH is planning to begin clinical trials of viral vaccine candidates to protect against Dengue virus and Chikungunya virus infections before year-end, following successful preclinical proof of concept studies. Read More
• Oculus Innovative Sciences Inc., of Petaluma, Calif., disclosed a 1-for-7 reverse split of its common stock (NASDAQ:OCLS) will be effective at the open of business on April 1, 2013. Read More
• Retina Institute Japan K.K. (RIJ), of Fukuoka, Japan, and Dainippon Sumitomo Pharma Co. Ltd. (DSP), of Osaka, Japan, signed an agreement under which DSP invests into RIJ to discuss an alliance that would put iPS cell technology for age-related macular degeneration to practical use. Read More
A team at Virginia Polytechnic Institute and State University genetically engineered Aedes aegypti mosquitoes to change their eye color, showing that it is possible to use a set of genome-editing tools known as TALENS to disrupt gene functioning in what the authors called a "non-traditional" species for the technology. Read More
